Stocks closed out a volatile week on November 13 with the major indexes pointing in different directions. The S&P 500 fell 0.40% to 7,561.67, the Nasdaq Composite lost 0.91% and the Dow Jones Industrial Average rose 0.10%.
For the full week, the S&P 500 gained 2.51%, the Nasdaq added 2.27% and the Dow rose 2.07%. The S&P 500 and the Nasdaq both snapped four-week losing streaks.
Chip Stocks Lead a Selloff as Confidence in the AI Trade Slips
Technology led the declines on November 13. The S&P 500 technology sector fell 1.7%, the worst of the 11 major sectors, and the Philadelphia Semiconductor Index dropped 3.4%. Decliners outnumbered advancers 1.61-to-1 on the Nasdaq.
Volatility rose too. The VIX ended at 19.30, up 3.2% on the day, after climbing above 20 in morning trading.
Anthony Saglimbene, chief market strategist at Ameriprise Financial, said “there’s been a loss of confidence” in the AI trade and expects volatility as bulls and bears contest its direction. Goldman Sachs strategist Kamakshya Trivedi said AI investment growth will likely peak in early 2027, which he called “a manageable event” for the broader economy but possibly a bigger test for markets.
Readers following the selloff can find more names in our list of oversold AI stocks where analysts see 50%+ upside.
Hot Producer Prices and Rate Hike Bets Weigh on Valuations
The Bureau of Labor Statistics reported that the October producer price index rose 0.3% from September, a little cooler than the 0.4% economists expected. The annual rate of 6.5% was still the largest since November 2022.
The 10-year Treasury yield reached 5.17% on November 13, its highest level since October. Traders fully price in a rate increase of at least 25 basis points at the Federal Reserve’s December meeting.
Federal Reserve Governor Michelle Bowman said on November 10 that rate hikes may be needed. San Francisco Fed President Mary Daly said her bias is that the central bank will have to raise its policy rate, and Boston Fed President Susan Collins said tighter policy is coming because inflation is high.
We also ranked aggressive growth stocks to buy according to Wall Street analysts in a separate piece.
Goldman Sachs strategist Peter Oppenheimer and his team forecast the S&P 500 at 8,700 for 2027, about 14% above its November 13 level. They expect earnings growth to slow but equities to keep rising, with high volatility along the way.

Our Methodology
To compile this list, we reviewed analyst rating initiations announced on Friday, November 13, 2026. We have ranked these stocks in ascending order of their average upside potential, as of November 13. We also list each stock’s number of hedge fund holders as of Q2 2026, from our database of 1,006 hedge funds.
At Insider Monkey, we are obsessed with what hedge funds do. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 612% since May 2014, beating its benchmark by 375 percentage points (see more details here).
10 Stocks That Just Hit Analysts’ Desks
10. Haemonetics (NYSE:HAE)
Average Upside Potential: 17%
Number of Hedge Fund Holders: 34
Jefferies initiated coverage of Haemonetics (NYSE:HAE) on November 13 with a Buy rating and a $150 price target. The firm cites a defensible technology advantage in plasma, where Haemonetics sells the machines and disposables used to collect plasma from donors. The company also sells hemostasis, cell salvage and transfusion management products to hospitals and blood collection systems to blood centers.
Jefferies called the return of plasma customer CSL the clearest validation of that technology and sees a clear path to wider margins. The second quarter of fiscal 2027, reported on November 5, gave the case some support. Revenue rose 9.3% from the second quarter of fiscal 2026 to $357.8 million, and the gross margin widened to 61.7% from 59.5% a year earlier. Organic revenue, which strips out currency and acquisitions, grew 10.0%, and adjusted earnings were $1.35 per share.
Management also raised its fiscal 2027 organic revenue growth guidance to a range of 6% to 9% from 4% to 7%, so the margin argument now sits on a higher revenue outlook than the one the company gave before the report.
9. Korn Ferry (NYSE:KFY)
Average Upside Potential: 20%
Number of Hedge Fund Holders: 31
Stephens initiated coverage of Korn Ferry (NYSE:KFY) on November 13 with an Overweight rating and a $94 price target. Korn Ferry is a global organizational consulting firm that advises companies on how to organize and pay their people, runs executive searches in four regions and handles recruiting that employers outsource. Its segments cover consulting, digital, executive search by region, and recruitment outsourcing with professional search.
The company reported its first quarter of fiscal 2027, which ended July 31, on September 9. Fee revenue rose 7% to $756.5 million, its sixth straight quarter of top-line growth, and adjusted earnings were $1.43 per share. Estimated remaining fees under existing contracts reached $1.9 billion, up 14% from a year earlier, and AMS, the recruitment outsourcing firm Korn Ferry acquired, is now part of the company.
Whether Korn Ferry can keep that run going with AMS in the fold is the question in our look at its talent business and its biggest bet. For the second quarter of fiscal 2027, management guided adjusted earnings of $1.30 to $1.40 per share, which sets the bar the next report will be measured against.
8. Analog Devices (NASDAQ:ADI)
Average Upside Potential: 20%
Number of Hedge Fund Holders: 102
Roth Capital initiated coverage of Analog Devices (NASDAQ:ADI) on November 13 with a Buy rating and a $505 price target. Analog Devices makes analog and mixed-signal chips, power management chips and sensors, and it sells software and digital platforms that run alongside them.
The growth behind the call is already in the numbers. Revenue in the third quarter of fiscal 2026, reported on August 19, reached $4.02 billion, up 40% from a year earlier. For the fourth quarter, the company guided to revenue of $4.3 billion, plus or minus $100 million. It completed its acquisition of Alif Semiconductor on November 3, and in a separate piece we looked at Analog Devices’ $1.35 billion bet on chips that let machines think for themselves.
The price is the other part of the argument. The shares trade at 23.65 times forward earnings, and the PEG ratio is 0.64, which sits below 1 because expected earnings growth is high relative to the multiple. Analog Devices is expected to report its next quarterly results on November 24, and analysts expect earnings of $3.88 per share.
7. Service Corporation International (NYSE:SCI)
Average Upside Potential: 23%
Number of Hedge Fund Holders: 24
Stephens initiated coverage of Service Corporation International (NYSE:SCI) with an Overweight rating and an $86 price target on November 13. The firm points to demographic trends that favor the business, a growing backlog of prepaid funeral and cemetery contracts, and cremation pressure it considers manageable. Service Corporation runs funeral homes, which handle cremations and burials, and cemeteries that sell interment rights and memorial spaces, in the United States and Canada.
The third quarter of 2026, which ended September 30 and was reported on October 28, was not a clean beat on costs. Revenue rose 5% from a year earlier. Adjusted earnings were $0.97 per share, up from $0.87 a year earlier, but the company lowered its 2026 adjusted earnings guidance to a range of $3.94 to $4.04. Chief Executive Officer Tom Ryan said elevated costs are expected to continue into the fourth quarter.
Sales made ahead of need were stronger. Comparable preneed sales production rose 6% at funeral homes and 5% at cemeteries in the third quarter of 2026. Those advance sales feed the backlog Stephens likes, so the debate on the stock is whether the revenue they add outruns the cost pressure Ryan described.
6. Power Integrations (NASDAQ:POWI)
Average Upside Potential: 32%
Number of Hedge Fund Holders: 20
Roth Capital initiated coverage of Power Integrations (NASDAQ:POWI) with a Buy rating and a $52 price target on November 13, arguing that new management’s cost reset lifted the earnings base faster than Wall Street models assumed. Power Integrations, based in San Jose, California, designs the chips that handle high-voltage power conversion, including AC-DC converters, LED drivers, gate drivers, motor drivers and automotive products. The company was founded in 1988.
The third quarter of 2026, reported on November 4, showed that earnings base at work. Revenue for the quarter ended September 30 was $125.5 million, up 6% from the third quarter of 2025, and non-GAAP earnings were $0.46 per share, compared with $0.36 a year earlier. Management will also raise its quarterly dividend to $0.22 per share in 2027.
Chief Executive Officer Jen Lloyd was direct about the weak spot. She said consumer products make up a third of sales and that demand there is soft. For the fourth quarter of 2026, the company guided revenue to a range of $118 million to $126 million, with the consumer weakness Lloyd described still in the mix.
5. Allegro MicroSystems (NASDAQ:ALGM)
Average Upside Potential: 59%
Number of Hedge Fund Holders: 24
Roth Capital initiated coverage of Allegro MicroSystems (NASDAQ:ALGM) on November 13 with a Buy rating and a $40 price target. Allegro, founded in 2013 and based in Manchester, New Hampshire, makes sensor chips that measure motion, speed, position and current, along with power chips that drive motors, manage power and run LED lighting.
Bulls argue that the company is gaining share in AI data centers and automotive safety systems, and that the extra chips it sells in each product are speeding up growth. The second quarter of fiscal 2027, which ended September 25 and was reported on October 29, fit that argument. Sales were $277 million, up 29% from a year earlier, with record data center sales. Non-GAAP earnings came to $0.26 per share.
Chief Executive Officer Mike Doogue said design wins, the contracts that put Allegro chips into customers’ future products, reached their highest quarterly level since the company’s initial public offering in 2020, up nearly 40% from a year earlier. Those wins take time to turn into sales, and management guided third quarter of fiscal 2027 sales to a range of $278 million to $288 million.
4. Alector (NASDAQ:ALEC)
Average Upside Potential: 74%
Number of Hedge Fund Holders: 25
Wells Fargo initiated coverage of Alector (NASDAQ:ALEC) on November 13 with an Overweight rating and a $7 price target. The firm says sentiment on the stock is negative after setbacks in its progranulin program and expects clinical data for its AL137 antibody to close the valuation gap. Alector, based in South San Francisco, is a clinical-stage biotech that develops treatments aimed at the immune system of the brain.
Wells Fargo’s case rests on a transferrin receptor approach to getting drugs into the brain for Alzheimer’s disease. The company’s third quarter of 2026, reported on November 5, added money behind it. Genentech took an exclusive global license to AL050, paying $100 million upfront with up to $1.17 billion in milestone payments to come.
Alector ended the third quarter of 2026 on September 30 with $138.7 million in cash, cash equivalents and investments, which the company says funds operations into the second half of 2029. AL137 has not yet been given to people. Alector plans first-in-human dosing in Australia no later than April 2027, so the data Wells Fargo is waiting for are still a long way off.
3. Denali Therapeutics (NASDAQ:DNLI)
Average Upside Potential: 91%
Number of Hedge Fund Holders: 35
Wells Fargo initiated coverage of Denali Therapeutics (NASDAQ:DNLI) with an Overweight rating and a $35 price target on November 13, calling this an inflection point for the company’s transferrin receptor technology. Denali, based in San Francisco, develops drugs for neurodegenerative diseases, with a pipeline that includes programs aimed at LRRK2, RIPK1, TREM2 and Tau.
The firm points to the approval of Avlayah, constructive FDA feedback on zafinofusp and Roche’s trontinemab data as validation of that approach, and it says cash flows from Avlayah and zafinofusp give the stock a floor value. Sales are early but climbing, and the company reported them on November 3. Avlayah brought in $17.8 million in net product revenue in the third quarter of 2026, its second full commercial quarter, and the company guided to $30.0 million to $32.0 million for the fourth quarter of 2026. The company also said coverage reaches above 70% of US commercial lives.
Wells Fargo is cautious on one front. It sees Hunter syndrome and Sanfilippo syndrome as small markets and Alzheimer’s as more competitive, with little room to stand apart from Roche’s trontinemab. Denali ended the third quarter of 2026 with about $1.01 billion in cash, cash equivalents and marketable securities.
2. INNIO (NASDAQ:INIO)
Average Upside Potential: 108%
Number of Hedge Fund Holders: 55
Piper Sandler initiated coverage of INNIO (NASDAQ:INIO) on November 13 with an Overweight rating and a $21 price target. The firm says data center developers are turning to gas engines for their own power because grid connections can take six years or more and turbines are sold out. INNIO is a global energy technology company that serves industrial, commercial, utility and infrastructure customers. It builds the Jenbacher gas engines and sells services over their lives, including long-term service agreements, spare parts and overhauls. Its equipment segment sells new engines and related equipment for data centers, power solutions and compression.
The third quarter of 2026, reported on October 27, was the company’s first with more than $1 billion in revenue, which reached $1.17 billion, up 57% from a year earlier. Data center revenue was $463 million. The pull from that market is also the subject of a piece we wrote on a mystery buyer’s 450-megawatt bet on INNIO’s gas engines.
Piper Sandler estimates INNIO will sell about 6 gigawatts to data centers over two years. That volume underpins its 2028 estimates of $6.25 billion in revenue and $1.45 billion in adjusted EBITDA.
1. Ultra Clean (NASDAQ:UCTT)
Average Upside Potential: 128%
Number of Hedge Fund Holders: 44
Barclays initiated coverage of Ultra Clean (NASDAQ:UCTT) on November 13 with an Equal Weight rating and a $65 price target, tying the company to a forecast surge in spending on chip equipment. Barclays expects wafer fab equipment spending to grow 32% in 2027 and 21% in 2028, and it says Ultra Clean’s results track that spending closely.
Ultra Clean designs and makes production tools, modules and subsystems for the semiconductor and display equipment industry. It supplies critical subsystems, components and parts to the semiconductor equipment industry and runs ultra-high purity cleaning services for chipmaking parts, including recoating of process tool parts and surface encapsulation. Applied Materials and Lam Research together account for most of its revenue, so its fortunes depend on two customers.
The third quarter of 2026, which ended September 25 and was reported on October 27, set a record. Revenue reached $759 million, up 49% from the third quarter of 2025, and the company guided to $800 million to $860 million for the fourth quarter of 2026. Under its at-the-market program, Ultra Clean sold new shares worth $169.1 million through October 28.
READ NEXT: Could Cadence Design (CDNS) and Analog Devices (ADI) Capture More of the Smart-Vehicle Opportunity? and Korn Ferry (KFY) Grew Contracted Fees 14%. Can AMS Add Growth Without Squeezing Margins?





